-       ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the ...

•  Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outcomes and limited viable treatment options
  
  
• ATNM-400 overcomes HER2 therapy resistance ...
  ]]>https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-announces-atnm-400-data-demonstrating-potent-efficacy-in-triple-negative-breast-cancer-and-ability-to-overcome-endocrine-and-her2-targeted-therapy-resistance-being-present-15324946Mon, 17 Nov 2025 06:35:07 +0100https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-zog-bilanz-zum-juengsten-jahresviertel-15282524Actinium Pharmaceuticals hat am 14.11.2025 die Bücher zum am 30.09.2025 abgelaufenen Quartal geöffnet.Das EPS lag bei -0,16 USD. Ein Jahr zuvor waren -0,370 USD je Aktie erzielt worden.Redaktion ...
  ]]>https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-zog-bilanz-zum-juengsten-jahresviertel-15282524Tue, 04 Nov 2025 13:30:00 +0100https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-inc-to-highlight-atnm-400-data-in-hormone-resistant-and-her2-resistant-breast-cancer-at-the-2025-san-antonio-breast-cancer-symposium-expanding-pan-tumor-profile-across-15185011

  - New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new treatment options beyond tamoxifen and trastuzumab

  ]]>https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-inc-to-highlight-atnm-400-data-in-hormone-resistant-and-her2-resistant-breast-cancer-at-the-2025-san-antonio-breast-cancer-symposium-expanding-pan-tumor-profile-across-15185011Mon, 03 Nov 2025 14:30:00 +0100https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-inc-to-participate-in-the-stephens-biotechnology-virtual-fireside-chat-conference-15176372

  NEW YORK, Nov. 3, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader ...

  ]]>https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-inc-to-participate-in-the-stephens-biotechnology-virtual-fireside-chat-conference-15176372Mon, 27 Oct 2025 12:00:00 +0100https://www.finanzen.net/nachricht/aktien/actinium-announces-superior-anti-tumor-activity-of-atnm-400-in-lung-cancer-compared-to-the-leading-first-second-and-third-line-approved-egfr-mutant-therapies-and-mechanistic-synergy-with-osimerti-15125172

  -  ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO^®), second line therapy Dato-DXd (Trop-2 ADC ...

  ]]>https://www.finanzen.net/nachricht/aktien/actinium-announces-superior-anti-tumor-activity-of-atnm-400-in-lung-cancer-compared-to-the-leading-first-second-and-third-line-approved-egfr-mutant-therapies-and-mechanistic-synergy-with-osimerti-15125172Fri, 24 Oct 2025 14:30:00 +0200https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-presents-new-data-demonstrating-potent-and-durable-efficacy-of-atnm-400-a-first-in-class-multi-tumor-actinium-225-radiotherapy-at-the-32nd-annual-prostate-cancer-foundat-15115679

  - ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology with
  continued expression following androgen receptor pathway inhibitor (ARPI) therapy
  and 177Lu-PSMA-617 therapy, ...

  ]]>https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-presents-new-data-demonstrating-potent-and-durable-efficacy-of-atnm-400-a-first-in-class-multi-tumor-actinium-225-radiotherapy-at-the-32nd-annual-prostate-cancer-foundat-15115679Mon, 13 Oct 2025 18:10:00 +0200https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-to-unveil-the-multi-tumor-potential-of-atnm-400-a-first-in-class-actinium-225-radiotherapy-with-data-in-non-small-cell-lung-cancer-at-the-aacr-nci-eortc-international-co-15032226
  • ATNM-400 is advancing as a first-in-class, multi-tumor Actinium-225 radiotherapy candidate with activity across prostate and lung cancers, two of the largest cancer indications globally
  • New ...
    ]]>https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-to-unveil-the-multi-tumor-potential-of-atnm-400-a-first-in-class-actinium-225-radiotherapy-with-data-in-non-small-cell-lung-cancer-at-the-aacr-nci-eortc-international-co-15032226Mon, 13 Oct 2025 14:30:00 +0200https://www.finanzen.net/nachricht/aktien/actinium-to-present-atnm-400-preclinical-data-highlighting-durable-tumor-control-and-ability-to-overcome-resistance-to-standard-of-care-prostate-cancer-therapies-at-the-32nd-annual-prostate-cancer-15029589

    -   ATNM-400 targets a highly differentiated, non-PSMA antigen associated with the development and progression of prostate cancer, exhibiting potent therapeutic activity independent of PSMA expression ...

    ]]>https://www.finanzen.net/nachricht/aktien/actinium-to-present-atnm-400-preclinical-data-highlighting-durable-tumor-control-and-ability-to-overcome-resistance-to-standard-of-care-prostate-cancer-therapies-at-the-32nd-annual-prostate-cancer-15029589